Cargando…
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery
BACKGROUND: The ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driven interest in identifying small-molecule-immunotherapy combinations to increas...
Autores principales: | Taylor, Molly A., Hughes, Adina M., Walton, Josephine, Coenen-Stass, Anna M. L., Magiera, Lukasz, Mooney, Lorraine, Bell, Sigourney, Staniszewska, Anna D., Sandin, Linda C., Barry, Simon T., Watkins, Amanda, Carnevalli, Larissa S., Hardaker, Elizabeth L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883640/ https://www.ncbi.nlm.nih.gov/pubmed/31779705 http://dx.doi.org/10.1186/s40425-019-0794-7 |
Ejemplares similares
-
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity
por: Carnevalli, Larissa S., et al.
Publicado: (2018) -
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
por: Langdon, Sophie, et al.
Publicado: (2018) -
A multi-batch design to deliver robust estimates of efficacy and reduce animal use – a syngeneic tumour case study
por: Karp, Natasha A., et al.
Publicado: (2020) -
Characterization of immune cell populations in syngeneic murine tumor models
por: Snipstad, Sofie, et al.
Publicado: (2023) -
A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability
por: Kuczynski, Elizabeth A, et al.
Publicado: (2022)